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Abstract
Purpose: The purpose of this work was to investigate the dosimetric impact of

2
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University, Toronto, ON, Canada

mixed energy (6‐MV, 15‐MV) partial arcs (MEPAs) technique on prostate cancer
VMAT plans.

Author to whom correspondence should be
addressed. Shadab Momin
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Methods: This work involved prostate only patients, planned with 79.2 Gy in 44
fractions to the planning target volume (PTV). Femoral heads, bladder, and rectum
were considered organs at risk. This study was performed in two parts. For each of
the 25 patients in Part 1, two single‐energy single‐arc plans, a 6 MV‐SA plan and a
15 MV‐SA plan, and a third MEPA plan involving composite of 6‐MV anterior–posterior partial arcs and a 15‐MV lateral partial arc weighted 1:2 were created. The
dosimetric difference between MEPA(6/15 MV 1:2 weighted) and 6 MV‐SA plans,
and MEPA(6/15 MV 1:2 weighted) and 15 MV‐SA plans were measured. In the Part
2 of this study, a second MEPAs plan (6 MV anterior–posterior arcs and 15 MV lateral arcs weighted 1:1), (MEPA 6/15 MV 1:1 weighted), was generated for 15
patients and compared only with two single‐energy partial arcs plans, a 6 and a
15 MV‐PA, to investigate the inﬂuence of the energy only. Dosimetric parameters
of each structure, total monitor‐units (MUs), homogeneity index (HI), and conformity
number (CN) were analyzed.
Results: In Part 1, no statistically signiﬁcant differences were observed for mean
dose to PTV and CN for MEPAs (6/15 MV 1:2 weighted) vs 6 and 15 MV‐SA.
MEPAs (6/15 MV 1:2 weighted) increased HI compared to 6 and 15 MV‐SA
(P < 0.0005; P < 0.0005). MEPAs (6/15 MV 1:2 weighted) produced signiﬁcantly
lower mean doses to rectum, bladder, and MUs/fraction, but higher mean doses to
femoral heads, compared to 6 MV‐SA (P < 0.0005) and 15 MV‐SA (P < 0.0005).
The results of Part 2 of this study showed that, in comparison to 6 and 15 MV‐PA,
MEPAs (6/15 MV 1:1 weighted) plans signiﬁcantly improved CNs (P < 0.0005;
P < 0.0005) and produced signiﬁcantly lower mean doses to the rectum and bladder
(P < 0.0005; P < 0.0005). While mean doses to the PTV and femoral heads of
MEPAs (6/15 MV 1:1 weighted) plans were statistically comparable to 6 MV‐PA
(P > 0.05), MEPAs (6/15 MV 1:1 weighted) increased mean doses to left (P = 0.04)
and right (P = 0.04) femoral heads compared to 15 MV‐PA. MEPAs (6/15 MV 1:1
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weighted) resulted in signiﬁcantly lower total MUs compared to 6 MV‐PA
(P < 0.0005) and 15 MV‐PA (P = 0.04).
Conclusion: The study for prostate radiotherapy demonstrated that a choice of
MEPAs for VMAT has the potential to minimize doses to OARs and improve dose
conformity to PTV, at the expense of a moderate increase in mean dose to the
femoral heads.
KEY WORDS

mixed energy VMAT, optimization, treatment planning

1 | INTRODUCTION

single energy IMRT for deep seated targets.12,13 While Park et al.12
performed a sequential optimization of photon beam energy (i.e.,

The main goal of radiation therapy is to provide dose conformity to the

generation of 6 MV ﬂuence maps followed by 15 MV ﬂuence maps)

target in four dimensions of space and time while minimizing the dose

using a commercial treatment‐planning software, McGeachy et al.13

to the normal tissues and organs at risk. Early techniques used geomet-

performed simultaneous optimization of photon beam energy and

ric ﬁeld shaping alone involving blocks or multileaf collimators (MLC) to

ﬂuence maps using an external optimizer. Nonetheless, both studies

conform to the target volume. Subsequently, intensity modulated radia-

showed that mixed energy IMRT improved overall quality of the

tion therapy (IMRT) allowed modulation of ﬂuence across the geometri-

treatment plans including better sparing of OARs.

cally shaped ﬁeld by using multiple radiation beams of nonuniform

To our knowledge, for VMAT, only one study has investigated

intensities. Currently, IMRT is widely practiced in clinics owing to its

the dosimetric inﬂuence of mixed energy VMAT approach for pros-

dosimetric advantages such as superior target dose conformity and bet-

tate cancer.14 Pokharel compared the mixed energy full arcs VMAT

ter OARs sparing.1 During the last decade, volumetric modulated arc

plans (a composite of 6 MV primary plan and 16 MV boost plan) with

therapy (VMAT) using modulated arcs is gaining popularity due to its

a single‐energy full arcs VMAT plans of either low or high energy.

improved efﬁciency compared to IMRT. VMAT involves the simultane-

Pokharel reported mixed energy VMAT plans to be superior over a

ous rotational movement between the linear accelerator along with

single‐energy VMAT plans in better sparing of OARs while maintain-

varying dose rate, gantry speed, and the shaping of multileaf collimator

ing dose conformity to the target. Since the current commercial

(MLC) leaves to produce modulated ﬂuence while the beam is on. It has

VMAT optimizers are not capable of optimizing a single plan with

been reported by a number of studies that VMAT results in improved

more than one energy, a mixed energy VMAT plan can only be cre-

delivery efﬁciency than IMRT for various types of cancer.2–7 A compre-

ated by combining two or more individual plans.15 In this work, we

hensive meta‐analysis on preferred technique in prostate treatment has

created mixed energy partial arcs (MEPAs) plans by manually merging

shown that, in addition to improvement in the delivery efﬁciency,

a 6 MV partial arcs plan and a 15 MV partial arcs plan. To our knowl-

VMAT also protects OARs better than IMRT for prostate cancer.8

edge, the investigation on the dosimetric impacts of MEPAs on

Both IMRT and VMAT utilize inverse planning algorithms for opti-

VMAT plans for prostate has not been reported in the literature. The

mization of dose to target and OARs. A clinically available optimization

aim of this work, therefore, was to further explore the scope of using

software optimizes ﬂuence map for each beam angle to achieve dose‐

two mixed energy VMAT techniques for prostate cancer by:

volume objectives. However, it does not optimize for couch angle or
photon energy. The selection of these parameters depends on the

• evaluating the additive effects of photon energy and dose weight-

tumor location and the experience of a treatment planner. The prefer-

ing in Part 1 through dosimetric comparisons of MEPAs (6/

ence on selection of photon beam energy for deep seated targets var-

15 MV 1:2 weighted) plans with 6 MV single-arc (6 MV-SA) plans

ies due to various energy‐related dosimetric consequences. For

and 15 MV single-arc (15 MV-SA) plans.

instance, use of low energy photon beams (≤6 MV) generates narrow

• investigating the sole effect of photon beam energy in Part 2

penumbra, which results in tighter dose distribution around the target.

through dosimetric comparisons of an equal dose weighted MEPAs

However, for deep seated targets, it may result in a higher surface

(6/15 MV 1:1 weighted), with 6 MV only partial arcs, (6 MV-PA)

dose. Higher energy photon beams, on the other hand, increase for-

plans, and 15 MV only partial arcs (15 MV-PA plans) plans.

ward scattering of electrons and photons, resulting in a low skin dose,
but may result in undesirable dose to the patient from secondary neutrons (especially for 18 MV). A number of previous studies for prostate
cancer reported dosimetric beneﬁts of using a higher energy photon
beam over 6 MV photon beam.9–12

2 | MATERIALS AND METHODS
2.A | Patient selection

Only a handful of studies, however, have compared dosimetric

A cohort of 25 patients with intermediate risk of prostate cancer

results of mixed energy (both low and high MV) IMRT plans with a

who underwent radiation therapy was randomly selected for Part 1
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of this study. A subset of 15 patients was randomly selected for the

treatment plan was to cover 95% of the PTV volume by at‐least

Part 2 of this study. For both studies, mean and standard deviation

95% of the PD with no more than 2% of the PTV receiving 107%.

of planning measurements such as anterior‐posterior separation, lat-

The dosimetric constraints were originally derived based on the

eral separation, planning target volume (PTV), bladder, rectum, and

quantitative analysis of normal tissue effects (QUANTEC) require-

femoral head volumes are summarized in Table 1. Figure 1 illustrates

ment for prostate cancer.17 For OARs, the goal was to meet the clin-

the steps taken in generating MEPAs plans and their comparisons

ically acceptable dose‐volume requirements as shown in Table 2.

with single energy plans in each part of the study.

2.C.1. | Treatment Plans
2.B | CT simulation and contouring

For each of the 25 patients in the Part 1 of the study, three volu-

Computed tomography (CT) scanning and simulations were per-

metric modulated arc plans were generated using the RapidArc™

formed using Philips Brilliance Big Bore Scanner (Philips Medical,

module in Eclipse™: (a) 6 MV plan using a SA, (b) 15 MV plan using

Cambridge, MA) with patients in a supine position and by following

a SA, (c) composite plan using 6 MV anterior–posterior partial arcs,

the standard CT scan protocol. The thickness of each CT image in

and 15 MV lateral arcs weighted 1:2 called MEPAs (6/15 MV 1:2

axial dimension was 1.5 mm. The contouring of prostate, left femur,

weighted).

right femur, bladder, and rectum was performed by a radiation

The dosimetric outcome of MEPAs (6/15 MV 1:2 weighted) plans

oncologist on the axial slices of the CT using the Varian Eclipse™

in part 1 of this study may result from additive effects of unequal

treatment planning system version 13.7 (Varian Medical Systems,

dose weighting and the energy. Furthermore, RapidArc™ TPS for

Palo Alto, CA). The OARs included bladder, rectum, left, and right

VMAT is an aperture/control point based optimization algorithm,

femur. The OAR volumes were contoured according to the radiation

which may act slightly different for single‐energy single‐arc vs single‐

16

The prostate was

energy partial arcs. Therefore, to eliminate this effect in addition to

deﬁned as a clinical target volume from which the PTV was gener-

unequal dose weighting, in Part 2, we performed another study with

ated by adding a 5 mm margin in all directions. Mean PTV volume

15 patients in which MEPAs plans weighted 1:1 called MEPAs (6/

was 86 ± 25 cc.

15 MV 1:1 weighted) were compared with the 6 MV only partial

therapy oncology group (RTOG‐0815) protocol.

arcs plans (6 MV‐PA) and 15 MV only partial arcs (15 MV‐PA) plans.

2.C | Treatment planning and optimization

Thus, the Part 2 of this study would essentially evaluate the inﬂuence of photon beam energy only.

In both parts of this study, the total prescription dose (PD) was
79.2 Gy in 44 fractions, with a daily dose of 180 cGy. The goal of

2.C.2. | Gantry and collimator settings

T A B L E 1 Summary of planning measurements for both parts of the
study

In Part 1 of this study, the gantry angle was set to rotate clockwise
(6/15 MV 1:2 weighted), the arc start and stop angles for a 6 MV

Studies
First part

Comparison

MEPAs(6/15 MV 1:2
weighted) vs 6 MV‐SA
and 15 MV‐SA,
respectively

Sample size

25

from 181° to 179° for 6 MV‐SA and 15 MV‐SA plans. For MEPAs

Second part
MEPAs(6/15 MV
1:1 weighted)
vs 6 MV‐PA
and 15 MV‐PA,
respectively
15

Age (yr)

67 ± 10

71 ± 9

A‐P separation
(cm)

23 ± 3

24 ± 3

Lateral separation
(cm)

39 ± 6

40 ± 5

PTV volume (cc)

86 ± 25

85 ± 18

Bladder volume
(cc)

251 ± 115

229 ± 96

Rectum
volume (cc)

74 ± 34

81 ± 36

Right femur
volume (cc)

182 ± 20

188 ± 21

Left femur
volume (cc)

181 ± 21

187 ± 23

were 181°–225°, 315°–45°, and 135°–179° rotating clockwise,
whereas for a 15 MV plan were 225°–315° and 45°–135° rotating
clockwise (Fig. 2).
In Part 2, the arc arrangement for MEPAs (6/15 MV 1:1
weighted), 6 MV‐PA (6 MV as anterior–posterior arcs and 6 MV as
lateral arcs) and 15 MV‐PA (15 MV as anterior–posterior arcs and
15 MV as lateral arcs) were same as the one for MEPAs (6/15 MV
1:2 weighted).
In both parts, the collimator angle was set to 90° for all plans as
it is considered to be a good choice for better OARs sparing in prostate cancer VMAT.18 The isocenter was placed at the center of mass
of the PTV for all the plans.

2.C.3. | Optimization parameters
In Part 1 of this study, two separate single‐energy single‐arc (a
6 MV‐SA plan and a 15 MV‐SA) plans were generated by setting the
optimization objectives, dose volume constraints and priority weighting factors as illustrated in (Table 3). For MEPAs, the following steps
were followed:
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Study Design for Part 1

Study Design for Part 2

6MV – PA (1/3 dose weighted)
plan optimization

6MV – PA (1/2 dose weighted)
plan optimization

15MV – PA (2/3 dose weighted)
plan optimization
Here, 6MV-PA 1/3 dose weighted
plan was set as a base plan

15MV – PA (1/2 dose weighted)
plan optimization
Here, 6MV-PA 1/2 dose weighted
plan was set as a base plan

Summation (6MV-PA + 15MV-PA)

Summation (6MV-PA + 15MV-PA)

MEPAs (6/15MV 1:2 weighted)

MEPAs (6/15MV 1:1 weighted)

Plan
Comparisons

Plan
Comparisons

6MV – SA

15MV – SA

6MV – PA

15MV – PA

ET AL.

F I G 1 . Flow charts illustrating the steps
taken in generating mixed energy partial
arcs plans and their comparisons with
single energy plans in Part 1 (left) and Part
2 (right) of this study.

T A B L E 2 The QUANTEC based dose‐volume restrictions for OARs
including femoral heads, rectum, and bladder.
Femoral
heads

V50 < 5%

Rectum

V75 < 15%, V70 < 20%,
V65 < 25%, V60 < 35%, V50 < 50%

Bladder

V80 < 15%, V75 < 25%,
V70 < 35%, V65 < 50% Dmax < 65 Gy

Femoral heads V50 < 5% represents no more than 5% of either femoral
heads should receive a dose of 50 Gy or more. Dmax = Maximum Dose.

1. A 6 MV anterior and posterior partial arcs plan was created by
setting the optimization objectives, constraints, and weightings as
shown in (Table 3). The 6 MV partial arcs plan delivered 26.4 Gy
over 44 fractions.
2. A 15 MV lateral arcs plan was then generated by setting the

F I G 2 . Arc start and stop angles for a Volumetric Arc Therapy
(VMAT) mixed energy partial arcs plan using partial arcs in Eclipse
treatment planning system.

optimization objectives, constraints, and weightings as shown in
(Table 3). Since Eclipse does not allow mixing energies in RapidArc™ module, the 15 MV lateral arcs plan was optimized by

1:1 weighted) plans were generated by following the aforementioned

using the 6 MV anterior-posterior arcs plan as a base plan. The

steps 2 and 3, but with an equal dose weighting.

15 MV lateral arcs plan delivered 52.8 Gy over 44 fractions.

In both parts of this study, the beam arrangement (6 MV ante-

3. As a ﬁnal step, plans from the previous steps, 6 MV anterior-pos-

rior–posterior arcs and 15 MV lateral arcs) was selected based on

terior arcs plan and 15 MV lateral arcs plan were summated to

the anatomical location of the target and surrounding OARs, and

generate a MEPAs (6/15 MV 1:2 weighted) plan.

required photon beam penetrating power. The beam parameters,
optimization objectives, dose‐volume constraints, and weighting fac-

In the Part 2 of this study, 6 MV only partial arcs plans (6 MV‐
PA), 15 MV only partial arcs plans (15 MV‐PA), and MEPAs plans

tors were kept constant for the 25 patients studied in Part 1 and for
the 15 patients studied in Part 2.

weighted 1:1, MEPAs (6/15 MV 1:1 weighted), were generated by

To avoid hot spots in the normal tissue, normal tissue objective

using optimization parameters shown in Table 4. MEPAs (6/15 MV

(NTO) feature of Eclipse™ TPS was used with the priority of 100 in
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T A B L E 3 Dose volume constraints and priority factors set in
RapidArc™ treatment planning software for optimization of 25
patients in ﬁrst study involving MEPA(6/15 MV 1:2 weighted),
6 MV‐SA and 15 MV‐SA plans.
Structure
PTV

Vol (%)

Rectum

— Version 13.7.16) with a 2.5 mm calculation grid. PTV coverage
was evaluated by calculating conformity number (CN) as deﬁned
below.19,20

Dose (% of PD)

Priority factor

105%

250

101.1%

250

0

98.5%

150

12

50.6%

150

of the isodose (Vref was determined by converting isodose to structure

38

31.2%

150

feature in Eclipse), VT represents PTV volume. This conformity assess-

64

23.6%

150

ment in Eq. (1) accounts for both target coverage (the ﬁrst brackets)

0

104.0%

150

and the proximity of isodose line to the target (the second brackets). A

12

59.0%

150

CN value closer to 1 is considered a perfectly conformal plan.

39

39.6%

150

Similarly, the mean and maximum dose, and hotspot determined

0
100

Bladder

55

CNVan0 t Riet ¼


 

TVT;ref
TVT;ref

Vref
VT

(1)

where TVT,ref. represents the volume of the target volume covered by
the 95% of the isodose, Vref represents the total volume receiving 95%

14.2%

150

by D2% (dose received by 2% of PTV) were recorded for each case.

Left femur

0

50%

150

To evaluate the dose homogeneity within the PTV, the homogeneity

Right femur

0

50%

150

index (HI) was deﬁned as per ICRU83 by taking a ratio of difference

75

PD: prescribed dose; 6 MV‐SA: 79.2 Gy (PD); 15 MV‐SA: 79.2 Gy (PD);
6 MV‐partial arcs: 26.4 Gy (PD); 15 MV‐partial arcs: 79.2 Gy (PD); PTV:
planning target volume.

T A B L E 4 Dose volume constraints and priority factors set in
RapidArc™ treatment planning software for optimization of 15
patients in second study involving MEPA(6/15 MV 1:1 weighted), 6
and 15 MV‐PA plans.
Structure
PTV

Vol (%)

Rectum

plan is considered homogeneous if the value of HI is close to zero.

HI ¼

D2% D98%
D50%

(2)

For OARs, the volumes receiving 70, 50, 30, and 20 Gy (V70Gy,
V50Gy, V30Gy, and V20Gy) were calculated to evaluate various irradi-

Dose (% of PD)

Priority factor

ated volumes of bladder and rectum. The mean dose was calculated

105%

250

to evaluate dose to femoral heads.

101.1%

250

0

98.5%

35

between 15 MV‐SA and MEPAs in corresponding dosimetric param-

12

50.6%

35

eter were evaluated by using Eq. (3).14

38

31.2%

35

64

23.6%

35

0
100

Bladder

of D2% (dose delivered to 2% of the PTV) and D98% (dose delivered
to 98% of the PTV), and dose delivered to 50% of the PTV.21 The

The average differences between 6 MV‐SA and MEPAs, and

DQMV
avg ðxÞ ¼



1 n ðQMVSAÞi ðMEPAsÞi
∑i¼1
 100
n
ðQMVSAÞi

(3)

0

104.0%

35

12

59.0%

35

39

39.6%

35

75

14.2%

35

resents the dosimetric parameter to be analyzed, and n represents

In Eq. (3), Q represents beam energy that is, 6 or 15 MV, x rep-

Left femur

0

50%

35

the total number of patients, 25 for the ﬁrst part, and 15 for the

Right femur

0

50%

35

second part. Since current standards of care use single arc with sin-

PD: Prescribed dose; 6 MV‐PA: 79.2 Gy (PD); 15 MV‐PA: 79.2 Gy (PD);
6 MV‐partial arcs: 39.6 Gy (PD); 15 MV‐partial arcs: 79.2 Gy (PD); PTV:
planning target volume.

gle energy, they were compared to the MEPAs. The 6 MV‐SA plans
and 15 MV‐SA plans were used as standard plans to evaluate the
average difference (Davg) between 6 MV‐SA and MEPAs (6/15 MV

combination with the falloff value of 0.05 cm . The NTO distance

1:2 weighted), and 15 MV‐SA and MEPAs (6/15 MV 1:2 weighted).

from the target border, start dose, and end dose were 1 cm, 105%,

This was repeated for the Part 2 in which 6 and 15 MV‐PA plans

and 60%, respectively. No normalization was required in both studies

were used as standard plans to evaluate the average difference

−1

to achieve dosimetric goals of the treatment.

between 6 MV‐PA and MEPAs (6/15 MV 1:1 weighted), and 15 MV‐
PA and MEPAs (6/15 MV 1:1 weighted).

2.D | Dosimetric parameters
The dose volume histograms (DVH) were generated for each plan in

2.E | Statistical analysis

Eclipse for dosimetric evaluation and comparison. The dose calcula-

In Part 1, the dosimetric parameters of MEPAs (6/15 MV 1:2

tion was performed with the anisotropic analytical algorithm (AAA

weighted) plans were statistically compared with the dosimetric

56

|

MOMIN

parameters of 6 and 15 MV‐SA using a two‐tailed paired‐sample t‐test.
In addition, the 95% conﬁdence interval is included for each P‐value.
In Part 2, the dosimetric parameters of MEPAs (6/15 MV 1:1

T A B L E 5 The dosimetric parameters for 6 MV‐SA, 15 MV‐SA, and
MEPAs (6/15 MV 1:2 weighted) plans. The data are averaged over
the cohort of 25 patients.
Structure

Dosimetric
parameter

PTV

weighted) plans were statistically compared with the dosimetric parameters of 6 and 15 MV‐PA using a two‐tailed paired‐sample t‐test.

ET AL.

Avg. ± SD
6 MV‐SA

Avg. ± SD
15 MV‐SA

Avg. ± SD
MEPAs

Max dose (Gy)

87.1 ± 1.2

86.6 ± 1.3

86.0 ± 1.2

are independent of each other and no cross comparison was done

95% CI (Gy)

86.6–87.6

86.0–87.1

85.2–86.7

between dosimetric parameters of the two parts. Statistical analysis

Mean dose (Gy)

81.1 ± 0.4

81.3 ± 0.6

81.2 ± 0.4

was conducted by using IBM SPSS Statistics 24 (IBM Corp. Released

95% CI (Gy)

80.9–81.3

81.1–81.6

81.0–81.4

2017. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY:

D2% (Gy)

83.9 ± 0.6

84.0 ± 0.7

84.0 ± 0.6

IBM Corp). For both studies, a P < 0.05 was considered to be statis-

95% CI (Gy)

86.7–84.2

83.7–84.3

83.7–84.3

tically signiﬁcant. Prior to two‐tailed t‐test, the data were checked

HI

0.08 ± 0.02

0.08 ± 0.02

0.09 ± 0.02

for normal distribution by performing the Shapiro–Wilk test.22

95% CI

0.08–0.09

0.08–0.09

0.09–0.1

CN

0.82 ± 0.04

0.82 ± 0.04

0.83 ± 0.05

95% CI

0.80–0.83

0.80–0.84

0.80–0.84

Max dose (Gy)

85.9 ± 1.7

85.5 ± 1.6

84.6 ± 1.2

95% CI (Gy)

85.3–86.6

84.9–86.3

84.1–85.1

Mean dose (Gy)

14.2 ± 6.6

14.1 ± 6.8

13.6 ± 6.1

At this point, it is important to note that both parts of this study

3 | RESULTS
Bladder

3.A | Part 1
3.A.1 | Dosimetry
The dosimetric parameters averaged over 25 cases for the 6 MV‐SA,
15 MV‐SA, and MEPAs (6/15 MV 1:2 weighted) is highlighted in
Table 5. The statistical differences between 6 MV‐SA and MEPAs (6/

95% CI (Gy)

11.5–16.9

11.3–16.9

10.8–15.8

V70Gy (%)

4.2 ± 2.0

4.2 ± 2.0

4.1 ± 2.1

95% CI (%)

3.4–5.0

3.4–5.0

3.2–4.9

V50Gy (%)

8.9 ± 4.1

9.1 ± 4.4

8.5 ± 4.2

95% CI (%)

7.2–10.6

7.2–10.9

6.8–10.3

V30Gy (%)

17.4 ± 9.7

17.6 ± 9.9

15.7 ± 8.8

tum, and as well as number of Monitor Units (MU), CI, and HI are

95% CI (%)

13.3–21.4

13.5–21.7

12.1–19.3

shown in Table 7.

V20Gy (%)

22.9 ± 13.9

23.7 ± 13.8

21.2 ± 12.0

95% CI (%)

17.1–28.6

18.0–29.3

16.2–26.1

Max dose (Gy)

85.0 ± 1.7

84.8 ± 1.4

84.1 ± 1.4

95% CI (Gy)

84.3–85.7

84.3–85.4

83.5–84.6

Mixed energy partial arcs (6/15 MV 1:2 weighted) resulted in a lower

Mean dose (Gy)

25.3 ± 3.4

25.7 ± 3.8

23.0 ± 3.6

maximum dose to the PTV in comparison to 6 MV‐SA (P < 0.0005)

95% CI (Gy)

23.9–26.7

24.1–27.3

21.5–24.5

15 MV 1:2 weighted), and 15MV‐SA and MEPAs (6/15 MV 1:2
weighted) plans are shown in Table 6. The average differences,
15MV
D6MV
avg andDavg , for dosimetric parameters of the PTV, bladder, rec-

Rectum

3.A.2 | Doses to the PTV

and 15 MV‐SA (P < 0.0005). (Table 5). Mean doses to the PTV of

V70Gy (%)

6.6 ± 2.1

6.7 ± 2.1

7.1 ± 2.1

MEPAs (6/15 MV 1:2 weighted) plans was comparable to 15 MV‐SA

95% CI (%)

5.7–7.4

5.8–7.5

6.2–7.9

plans (P = 0.06), but higher compared to 6 MV‐SA (P = 0.01) plans

V50Gy (%)

15.2 ± 2.9

16.3 ± 3.5

15.8 ± 3.8

(Tables 5 and 6). The D2% of the PTV of MEPAs (6/15 MV 1:2

95% CI (%)

14.0–16.4

14.8–17.7

14.3–17.4

weighted) plans was comparable to both 6 MV‐SA (P = 0.67) and

V30Gy (%)

40.1 ± 5.8

40.1 ± 7.1

31.4 ± 6.8

15 MV‐SA (P = 0.87) plans (Table 6).

95% CI (%)

37.7–42.5

37.5–43.3

28.6–34.2

V20Gy (%)

52.2 ± 8.0

53.2 ± 8.6

42.4 ± 7.2

95% CI (%)

48.9–55.5

49.6–56.7

39.4–45.4

Mean dose (Gy)

11.1 ± 2.2

11.0 ± 2.2

14.9 ± 3.1

95% CI (Gy)

10.2–12.0

10.1–12.0

13.6–16.2

Max dose (Gy)

30.7 ± 5.6

30.0 ± 5.2

39.6 ± 4.7

95% CI (Gy)

28.5–32.9

28.0–32.0

37.7–41.4

Mean dose (Gy)

10.9 ± 2.9

11.0 ± 2.3

15.3 ± 2.9
14.1–16.5

In comparison to 6 and 15 MV‐SA plans, MEPAs (6/15 MV 1:2
weighted) produced statistically equivalent conformity number
(P = 0.1), however, it resulted in slightly inferior target homogeneity
index

(P < 0.0005)

(Table 6).

A

negative

average

L femur

differ-

15MV
enceD6MV
avg andDavg , indicated higher values for HI of MEPAs (6/

15MV 1:2 weighted) plans (Table 7).
R femur

3.A.3 | Doses to the bladder
As indicated by positive values of

15MV
D6MV
avg andDavg

in Table 7, the

dosimetric parameters for bladder were always lower for MEPAs (6/
15 MV 1:2 weighted) plans compared to 6 and 15 MV‐SA plans
(Tables 5 and 7). MEPAs (6/15 MV 1:2 weighted) irradiated signiﬁcantly lower volume than 6 and 15 MV‐SA, with an exception of
V70Gy (P = 0.08) and V50Gy (P = 0.09) for 6 MV‐ SA (Tables 6 and 7).

95% CI (Gy)

9.8–12.2

10.0–12.1

Max dose (Gy)

30.9 ± 5.4

30.6 ± 5.6

40.5 ± 3.5

95% CI (Gy)

28.8–33.0

28.4–32.8

39.2–41.9

MUs
95% CI (MUs)

637 ± 84

514 ± 50

435 ± 104

602–673

493–535

398–474

MEPAs: mixed energy partial arcs; SA: single arc; PTV: planning target
volume; SD: standard deviation.
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T A B L E 6 Statistical comparison of dosimetric parameters between (a) 6 MV‐SA and MEPAs (6/15 MV 1:2 weighted) and (b) 15 MV‐SA and
MEPAs (6/15 MV 1:2 weighted). The dosimetric parameters are averaged over the cohort of 25 patients.
6MV‐SA vs MEPAs (1:2 weighted)
Structure

Dosimetric parameter

P‐value

PTV

Max dose (Gy)

<0.0005

Bladder

Rectum

Left femur

Right femur

95% CI
0.70, 1.59

15MV‐SA vs MEPAs (1:2 weighted)
P‐value
0.03

95% CI
0.07, 1.23

Mean dose (Gy)

0.01

−0.24, −0.03

0.06

−0.01, 0.24

D2% (Gy)

0.67

−0.26, 0.17

0.87

−0.18, 0.21

HI

<0.0005

−0.02, −0.01

<0.0005

−0.02, −0.005

CN

0.1

−0.02, 0.002

0.1

−0.02, 0.003

Max dose (Gy)

0.01

0.67, 2.00

<0.0005

0.21, 1.66

Mean dose (Gy)

<0.0005

0.49, 1.41

<0.0005

0.36, 1.36

V70Gy (%)

0.08

−0.02, 0.27

0.04

0.01, 0.27

V50Gy (%)

0.09

−0.06, 0.74

0.02

0.10, 0.97

V30Gy (%)

0.002

0.70, 2.65

<0.0005

1.01, 4.34

V20Gy (%)

0.02

0.21, 3.27

0.001

1.11, 3.87

Max dose (Gy)

0.001

0.42, 1.44

0.002

0.31, 1.18

Mean dose (Gy)

<0.0005

1.41, 3.08

<0.0005

1.74, 5.98

V70Gy (%)

0.005

−0.88, −0.18

0.01

−0.75, −0.10

V50Gy (%)

0.22

−1.61, 0.38

0.39

−0.62, 1.54

V30Gy (%)

<0.0005

6.52, 10.84

<0.0005

6.26, 11.7

V20Gy (%)

<0.0005

6.84, 12.72

<0.0005

7.72, 13.79

Mean dose (Gy)

<0.0005

−4.77, ‐2.79

<0.0005

−4.94, −2.78

Max dose (Gy)

<0.0005

−11.02, −6.78

<0.0005

−11.96, −7.19

Mean dose (Gy)

<0.0005

−5.53, −3.04

<0.0005

−5.43, −3.04

Max dose (Gy)

<0.0005

−11.53, −7.72

<0.0005

−11.83, −8.00

<0.0005

163.4, 239.6

<0.0005

43.14, 113.3

MUs

MEPAs: mixed energy partial arcs; SA: single arc; MUs: monitor units; Avg: average; PTV: planning target volume; SD: standard deviation; P ≤ 0.0005
represents a P value of 0.

This can also be observed in 95% CI for each P‐value, which

Tables 5 and 6). This difference can be observed by negative values

excludes the null value, zero, for signiﬁcance and includes the null

15MV
of D6MV
in (Table 7).
avg andDavg

value, zero, for insigniﬁcance. Furthermore, the maximum dose to
bladder exceeded 65 Gy for all three techniques without signiﬁcant
difference among three techniques. (Tables 5 and 6).

3.A.6 | Monitor units
The number of MUs was lower for MEPAs (6/15 MV 1:2 weighted)

3.A.4 | Doses to the rectum

plans by 202 and 79 MU compared to 6 MV‐SA (P < 0.0005) and
15 MV‐SA (P < 0.0005), respectively, (Tables 5 and 6).

The mean dose to the rectum was ~2 Gy lower for MEPAs (6/
15 MV 1:2 weighted) plans compared to 6 MV‐SA (P < 0.0005) and
15 MV‐SA (P < 0.0005) plans (Tables 5 and 6) with a positive aver15MV
of 9 ± 8% and 10 ± 8% (Table 7).
age difference D6MV
avg andDavg

3.A.7 | Dose distribution
The dose distributions in color‐wash view resulting from RapidArc™

MEPAs (6/15 MV 1:2 weighted) plans covered signiﬁcantly lower

planning with 6 MV‐SA, 15 MV‐SA, and MEPAs (6/15 MV 1:2

volume of rectum at V30Gy and V20Gy dose levels compared to

weighted) for one representative case in transverse plane is demon-

6 MV‐SA (P < 0.0005), and 15 MV‐SA (P < 0.0005), but not at sta-

strated in Fig. 3. MEPAs (6/15 MV 1:2 weighted) technique pro-

tistical signiﬁcance threshold for V50Gy (Tables 5 and 6).

duced tighter dose distribution in anterior‐posterior direction, where
bladder and rectum are close to the PTV, but produced wider dose

3.A.5 | Doses to the femoral heads

spread in lateral direction compared to 6 and 15 MV‐SA (Figure 3).
The DVHs for all three, a 6 MV‐SA, a 15 MV‐SA, and a MEPAs (6/

MEPAs (6/15 MV 1:2 weighted) resulted in an increased mean doses

15 MV 1:2 weighted), plans are shown in Fig. 4, which shows large

and maximum doses to both femoral heads by ~4.0 and ~10.0 Gy

differences in the volumetric doses to rectum and femoral heads

compared to 6 MV‐SA (P < 0.0005) and 15 MV‐SA (P < 0.0005;

among three techniques.
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T A B L E 7 The average difference, Davg (%), of dosimetric parameters between 6 MV‐SA and MEPAs (6/15 MV 1:2 weighted), and between
15 MV‐SA and MEPAs (6/15 MV 1:2 weighted)
Structure

Avgdiff ± SD.
6 MV‐SA vs MEPAs ðD6MV
Avg Þ

Dosimetric parameter

PTV

Min dose (%)

0 ± 4.0

1.0 ± 3.59

Max dose (%)

0.7 ± 3.3

0.9 ± 1.84

Mean dose (%)

Bladder

‐0.9 ± 3.6

L Femur

R Femur

0.3 ± 0.99

HI (%)

−22.4 ± 24.4

−19.0 ± 25.7

CN (%)

−1.3 ± 3.5

−1.1 ± 3.5

1.6 ± 1.9

1.1 ± 2.0

Max dose (%)

Rectum

Avgdiff. ± SD
15 MV‐SA vs MEPAs ðD15MV
Avg Þ

Mean dose (%)

6.2 ± 7.0

4.7 ± 7.1

V70Gy (%)

5.8 ± 13.7

5.7 ± 11.1

V50Gy (%)

5.3 ± 14.7

6.5 ± 13.0

V30Gy (%)

8.7 ± 13.2

10.2 ± 12.0

V20Gy (%)

5.3 ± 11.8

9.3 ± 10.7

Max dose (%)

1.1 ± 1.4

0.9 ± 1.2

Mean dose (%)

8.8 ± 7.7

10.1 ± 8.2

V70Gy (%)

−9.3 ± 17.1

−7.5 ± 14.6

V50Gy (%)

−4.0 ± 17.1

2.5 ± 15.7

V30Gy (%)

21.7 ± 12.9

21.6 ± 14.1

V20Gy (%)

18.2 ± 11.5

19.5 ± 11.4

Mean dose (%)

−35.5 ± 23.1

−37.4 ± 26.5

Max dose (%)

−31.9 ± 21.7

−34.6 ± 21.8

Mean dose (%)

−90.6 ± 277.0

−46.4 ± 24.7

Max dose (%)

−34.2 ± 21.4

−35.4 ± 20.6

MUs

29.8 ± 19.7

VnGy, in terms of data, represents the percentage of structure volume receiving n Gy or more.
ning target volume

12.9 ± 26.6
D6MV
Avg

and

D15MV
Avg

were calculated using Eq. (3). PTV: plan-

P < 0.0005) plans and 15 MV‐PA (0.83 vs 0.78; P < 0.0005) plans

3.B | Part 2

(Table 9). This can also be observed by negative average differences,

In this part of the study, MEPAs (6/15 MV 1:1 weighted) plans were

15MV
D6MV
avg andDavg , in Table 10. However, MEPAs (6/15 MV 1:1

compared with 6 MV only partial arcs (6 MV‐PA) and 15 MV only

weighted) plans produced inferior target homogeneity compared to

partial arcs (15 MV‐PA) for a cohort of 15 patients to evaluate the

6 MV‐PA plans (0.06 vs 0.07; P = 0.01) (Table 9).

inﬂuence of photon beam energy only.

3.B.2 | Doses to the Bladder
3.B.1 | Doses to the PTV

All the dosimetric parameters, except maximum dose to bladder,

No statistically signiﬁcant differences were observed between

were statistically lower for MEPAs (6/15 MV 1:1 weighted) plans

MEPAs (6/15 MV 1:1 weighted) and 6 MV‐PA, and MEPAs (6/

compared to 6 and 15 MV‐PA plans (Table 8 and 9). This difference

15 MV 1:1 weighted) and 15 MV‐PA for maximum doses to the

can also be observed in Table 10 by positive values of average dif-

PTV (Table 9). The mean doses to the PTV were statistically lower

15MV
ference, D6MV
avg and Davg , for both comparisons.

for MEPAs (6/15 MV 1:1 weighted) plans compared to 15 MV‐PA
plans (P < 0.0005; Tables 8 and 9), but no statistical signiﬁcance
was reached for mean doses to the PTV for comparison between
MEPAs

(6/15 MV

1:1

weighted)

plans

and

6 MV‐PA

plans

(Table 9).

3.B.3 | Doses to the rectum
Mean dose to the rectum for MEPAs (6/15 MV 1:1 weighted) plans
was ~4 Gy lower than 6 MV‐PA (P < 0.0005) and 15 MV‐PA plans

MEPAs (6/15 MV 1:1 weighted) plans signiﬁcantly improved the

(P < 0.0005; Tables 8 and 9). Furthermore, MEPAs (6/15 MV 1:1

dose conformity to the PTV compared to 6 MV‐PA (0.83 vs 0.77;

weighted) covered signiﬁcantly lower amount of rectal volume at all

MOMIN

ET AL.

F I G 3 . The dose distribution of a 6 MV‐
SA, a 15 MV‐SA, and a MEPAs (6/15 MV
1:2 weighted) plan with an equal dose
weight for one representative case in
transversal views.

F I G 4 . Dose volume histograms for 6 MV‐SA (Circles), 15 MV‐SA (Triangles), and MEPAs (6/15 MV 1:2 weighted) (Squares) for PTV in
yellow, rectum in brown, right femur in blue, left femur in pink, and bladder in clover‐lime.
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T A B L E 8 The dosimetric parameters for 6 MV‐PA, 15 MV‐PA, and MEPAs (6/15 MV 1:1 weighted). The dosimetric parameters are averaged
over the cohort of 15 patients.
Structure
PTV

Bladder

Rectum

Left femur

Right femur

Dosimetric parameter

Avg ± SD.
6 MV‐PA

Avg. ± SD
15 MV‐PA

Avg. ± SD
MEPAs

Max dose (Gy)

86.7 ± 0.9

86.0 ± 0.5

86.4 ± 1.2

95% CI (Gy)

86.3–87.3

86.7–86.3

85.8–87.1

Mean dose (Gy)

81.7 ± 0.4

82.1 ± 0.5

81.6 ± 0.3

95% CI (Gy)

81.4–81.9

81.8–82.4

81.4–81.8

D2% (Gy)

84.0 ± 0.4

84.2 ± 0.5

83.7 ± 0.4

95% CI (Gy)

83.8–84.2

83.9–84.5

83.5–84.0

HI

0.06 ± 0.01

0.07 ± 0.01

0.07 ± 0.1

95% CI

0.06–0.07

0.06–0.07

0.07–0.08

CN

0.77 ± 0.05

0.78 ± 0.05

0.83 ± 0.03

95% CI

0.75–0.80

0.75–0.81

0.81–0.84

Max dose (Gy)

85.7 ± 1.1

85.6 ± 1.1

85.6 ± 1.6

95% CI (Gy)

85.1–86.3

85.0–86.3

84.9–86.6

Mean dose (Gy)

17.5 ± 8.1

17.7 ± 7.8

15.2 ± 7.6

95% CI (Gy)

13.0–22.0

13.0–22.0

11.0–19.4

V70Gy (%)

5.0 ± 2.8

4.9 ± 2.6

4.2 ± 2.4

95% CI (%)

3.4–6.5

3.5–6.4

2.9–5.6

V60Gy (%)

7.8 ± 4.2

7.7 ± 4.1

6.7 ± 3.7

95% CI (%)

5.4–10.1

5.6–10.1

4.7–8.8

V45Gy (%)

13.2 ± 8.5

13.3 ± 7.9

11.1 ± 6.8

95% CI (%)

8.5–17.9

8.9–17.7

7.3–14.9

V15Gy (%)

32.1 ± 19.9

33.9 ± 19.6

29.3 ± 19.2

95% CI (%)

21.02–43.1

23.0–44.8

18.6–40.0

Max dose (Gy)

85.2 ± 1.4

84.9 ± 1.1

84.7 ± 1.5

95% CI (Gy)

84.4–86.0

84.3–85.5

83.9–85.6

Mean dose (Gy)

31.7 ± 4.4

32.4 ± 4.2

27.2 ± 4.8

95% CI (Gy)

29.4–34.2

30.1–34.7

24.6–30.0

V70Gy (%)

12.3 ± 5.9

11.7 ± 5.4

8.5 ± 3.6

95% CI (%)

9.0–15.6

8.7–14.7

6.5–10.5

V60Gy (%)

19.9 ± 8.4

19.4 ± 7.9

13.8 ± 4.2

95% CI (%)

15.2–24.6

15.1–23.8

11.5–16.2

V45Gy (%)

33.4 ± 9.9

32.3 ± 8.7

26.2 ± 5.1

95% CI (%)

28.0–38.9

28.2–37.8

23.4–29.1

V15Gy (%)

59.3 ± 10.8

60.4 ± 11.2

56.7 ± 11.3

95% CI (%)

53.3–65.3

54.2–66.6

50.5–63.0

Mean dose (Gy)

10.3 ± 2.9

10.1 ± 3.0

12.0 ± 2.7

95% CI (Gy)

8.8–11.9

8.4–11.8

10.6–13.5

Mean dose (Gy)

10.3 ± 2.4

10.0 ± 2.8

12.3 ± 2.9

95% CI (Gy)
MUs
95% CI (MUs)

8.9–11.6

8.5–11.5

10.7–13.9

553 ± 88

442 ± 57

480 ± 73

504–602

411–474

440–521

MEPAs: mixed energy partial arcs; PA: partial arc; PTV: planning target volume SD: standard deviation.

dose levels (V70Gy = 9%, V60Gy = 14%, V45Gy = 26% and V15Gy =
57%) compared to 6 MV‐PA (V70Gy = 12%, V60Gy = 20%, V45Gy =
33% and V15Gy = 59%) and 15MV‐PA (V70Gy = 12%, V60Gy = 19%,
V45Gy = 32% and V15Gy = 60%; Tables 8 and 9).

3.B.4 | Doses to the femoral heads
MEPAs (6/15 MV 1:1 weighted) resulted in increased mean doses to
right femur (P = 0.04) and left femur (P = 0.048) compared to
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T A B L E 9 Statistical comparison of dosimetric parameters between (a) 6 MV‐PA and MEPAs (6/15 MV 1:1 weighted) and (b) 15 MV‐PA and
MEPAs (6/15 MV 1:1 weighted) plans. The dosimetric parameters are averaged over the cohort of 15 patients

Structure

Dosimetric
parameter

PTV

Max dose (Gy)

Bladder

Rectum

6 MV‐PA vs MEPAs (1:1 weighted)
P‐value

95% CI

15 MV‐PA vs MEPAs (1:1 weighted)
P‐value

95% CI

0.34

−4.40, 1.19

0.16

Mean dose (Gy)

0.13

−0.04, 0.25

<0.0005

0.11, 0.3

D2% (Gy)

0.02

0.05, 0.50

0.002

0.21, 0.77

HI

0.01

−0.01, −0.003

0.05

−0.006, −0.03

CN

<0.0005

−0.07, −0.03

<0.0005

−0.008, 0.002

Max dose (Gy)

0.88

Mean dose (Gy)

−0.63, 1.52

0.99

−1.12, 0.21

−0.64, 0.87

<0.0005

2.1, 5.93

<0.0005

2.72, 6.59

V70Gy (%)

0.001

0.34, 1.06

<0.0005

0.44, 0.89

V60Gy (%)

0.001

0.51, 1.62

<0.0005

0.67, 1.63

V45Gy (%)

0.007

0.67, 3.57

0.001

1.16, 3.28

V15Gy (%)

0.001

Max dose (Gy)

0.75

Mean dose (Gy)

1.34, 4.42

0.001

−0.56, 0.65

0.39

2.27, 6.86
−0.87, 0.86

<0.0005

1.37, 3.1

<0.0005

1.53, 2.92

V70Gy (%)

0.001

1.93, 5.7

0.001

1.62, 4.71

V60Gy (%)

0.001

2.96, 9.19

0.001

1.29, 2.81

V45Gy (%)

0.007

2.37, 12.06

0.003

2.77, 10.74

V15Gy (%)

0.01

1.29, 3.92

<0.0005

2.41, 5.01

Left femur

Mean dose (Gy)

0.12

−3.83, 0.46

0.048

−3.8, −0.01

Right femur

Mean dose (Gy)

0.05

−3.98, 0.01

0.04

−4.36, −0.18

44, 100

0.04

−74, −2

MUs

<0.0005

MEPAs: mixed energy partial arcs; SA: single arc; MUs: monitor units; Avg: average; PTV: planning target volume; SD: standard deviation; P ≤ 0.0005
represents a P value of 0.

15 MV‐PA (Table 8 and 9). There is a noticeable difference in mean

4 | DISCUSSION

doses to femoral heads of MEPAs (6/15 MV 1:1 weighted) plans and
6 MV‐PA plans (Table 8), but no statistical signiﬁcance was observed

Manually choosing multiple photon energies in an IMRT plan is not

(P = 0.12 and P = 0.05 for left and right femur, respectively;

practiced very commonly except for a few clinical sites such as

Table 9).

breast. However, for VMAT, only a single energy approach is currently being used in the clinics, presumably due to lack of sufﬁcient

3.B.5 | Monitor units

evidences indicating superiority of using multiple energies over a single energy, and complexity arising due to several energies. In this

The total number of monitor units for MEPAs (6/15 MV 1:1

work, we investigated the dosimetric quality of two MEPAs tech-

weighted) plans was higher than that of 15 MV‐PA plans (480 vs

niques for prostate cancer VMAT. In Part 1, MEPAs (6/15 MV 1:2

442 MUs; P = 0.04; Tables 8 and 9) with an average negative differ-

weighted) plans reduced the total number of monitor units, while

ence of 9% (Table 10), but lower than that of 6 MV‐PA plans (480

sparing OARs and maintaining dose conformity to the PTV compared

vs 553 MUs; P < 0.0005; Tables 8 and 9) with an average positive

to standard 6 MV‐SA or 15 MV‐SA techniques. However, higher

difference of 13% (Table 10).

doses to femoral heads and slightly inferior HI of MEPAs (6/15 MV
1:2 weighted) plans should also be noted. Slightly degraded HI could

3.B.6 | Dose distribution

be due to the optimization parameters including priority weighting
factors, which, in this work, were kept the same to avoid biasing the

Figure 5 shows the dose distributions in color‐wash view for 6 MV‐

results. Greater emphasis on priority weighting factor can essentially

PA, 15 MV‐PA, and MEPAs (6/15 MV 1:1 weighted) plans for one

improve the HI. Lower doses to the bladder and rectum, and higher

representative case along sagittal views. MEPAs (6/15 MV 1:1

doses to the femoral heads by MEPAs (6/15 MV 1:2 weighted) plans

weighted) plans appear to produce a tighter dose distribution with

were likely to be the result of 6/15 MV 1:2 dose weighting. As a

the greater avoidance of OARs in comparison to 6 and 15 MV‐PA

result, a smaller dose proportion of PD by a lower energy (6 MV)

plans (Figure 5).

beam produced tighter dose distribution in anterior and posterior
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T A B L E 1 0 The average difference, Davg (%), of dosimetric
parameters between 6 MV‐PA and MEPAs (6/15 MV 1:1 weighted),
and between 15 MV‐PA and MEPAs (6/15 MV 1:1 weighted).
Avgdiff. ± SD
6 MV‐PA vs MEPAs
(D6MV
Avg )

Avgdiff. ± SD
15 MV‐PA vs
MEPA (D15MV
Avg )

ET AL.

eliminating the heuristic weighting scheme. This study showed that
MEPAs (6/15 MV 1:1 weighted) improved CN, reduced doses to
bladder and rectum by covering lower volume of OARs at all dose
levels, and lowered MUs, but increased doses to the femoral heads

Structure

Dosimetric
parameter

PTV

Min dose (%)

2.4 ± 3.0

2.7 ± 2.6

Max dose (%)

0.4 ± 1.7

−0.5 ± 1.4

plans (one energy per one arc) with a single‐energy dual arcs plans

Mean dose (%)

0.1 ± 0.3

0.7 ± 0.5

for prostate cases involving seminal vesicles and lymph nodes. Our

Bladder

VMAT technique,24 which compared dual arcs mixed energy VMAT

HI (%)

−11.2 ± 11.0

−6.9 ± 10.0

study involved comparison of a full arc split into MEPAs, MEPAs (6/

CN (%)

−6.8 ± 4.8

−6.4 ± 4.7

15 MV 1:1 weighted), with a single‐energy partial‐arc plans (6 and

Max dose (%)

0.1 ± 1.3

0 ± 1.8

15 MV‐PA) for prostate only. Furthermore, for prostate cancer

Mean dose (%)

14.0 ± 7.9

14.0 ± 7.6

patients with AP separation greater than 21 cm, the higher energy

V70Gy (%)

15.6 ± 13.7

15.9 ± 11.4

(10 MV) plans were reported to be superior in sparing OARs and

V60Gy (%)

14.7 ± 11.8

16.1 ± 12.1

lowering monitor units compared to lower energy (6 MV) plans.25

V45Gy (%)

15.9 ± 11.3

18.1 ± 10.3

In assessing clinical importance, it has been previously reported

10.6 ± 9.0

15.7 ± 12.1

that rectum volume receiving ≤30 Gy reduced the incidence of sev-

0.5 ± 2.2

0.1 ± 1.6

12.11 ± 9.0

13.9 ± 9.1

V15Gy (%)
Rectum

compared to 6 and 15 MV‐PA. The results of Part 2 of this study
are in agreement with the only previous study on mixed energy

Max dose (%)
Mean dose (%)
V70Gy (%)

26.6 ± 19.5

23.8 ± 18.8

V60Gy (%)

24.2 ± 21.5

23.7 ± 19.9

V45Gy (%)

17.3 ± 19.4

17.1 ± 18.1

V15Gy (%)

4.5 ± 3.7

6.3 ± 3.7

eral types of patient‐reported late rectal toxicities by 10%–18%.26
MEPAs (6/15 MV 1:2 weighted) reduced V30Gy by 9% compared to 6
and 15 MV‐SA (Table 5). The rectum volume receiving ≥60 Gy is
associated with late rectal complication,27 MEPAs (6/15 MV 1:1
weighted) technique reduced V60Gy by 6% compared to both 6 and
15 MV‐PA techniques (Table 8). It has been reported that late rectal
complications occurred in 3/7 patients and 4/7 patients when a dose

Left femur

Mean dose (%)

−26.0 ± 55.7

−26.1 ± 43.1

of 70 Gy or more was delivered to at least 7% and 3% of the rectal

Right femur

Mean dose (%)

−24.7 ± 40.1

−30.0 ± 43.5

volume, respectively.28 It should be noted that the V70Gy ranged from

12.6 ± 8.4

−9.4 ± 15.0

6% to 7% in Part 1 (Table 5) and 8% to 11% in Part 2 of this study

MUs

VnGy, in terms of data, represents the percentage of structure volume
15MV
receiving n Gy or more. D6MV
were calculated using Eq. (3).
Avg and DAvg
PTV: planning target volume.

(Table 8). In comparison to 6 and 15 MV‐SA, possible occurrences of
post‐EBRT rectal complications might be reduced by MEPAs (6/
15 MV 1:2 weighted) as it only delivers 1/3 of the PD with bladder
and rectum being in direct path of the beam. Complications in

regions of the PTV and a greater dose proportion of PD by a higher

femoral heads such as fractures and necrosis can be kept to less than

energy (15 MV) beam produced greater dose spread in the lateral

5% if the mean dose to <50 Gy to limit.29 Though MEPA (6/15MV

direction (Figure 3). All three plans (MEPAs [6/15 MV 1:2 weighted],

1:2 weighted) delivers 2/3 of the PD from lateral arcs, the mean dose

6 and 15 MV‐SA) met the QUANTEC criteria, except maximum dose

to the femoral heads were well below 20 Gy. According to Cefaro et

to bladder, due to not including the maximum dose constraint during

al., the likelihood of a fracture of the femoral heads is greater than

optimization.

5% when maximum dose to the femoral heads exceeds 40–45 Gy.30

With an exception of degraded HI and lower MUs, the results of

The maximum dose deposited to the left and right femur by MEPA

Part 1 of this study are in agreement with a previous study,14 which

(6/15 MV 1:2 weighted) technique was 38 and 41 Gy, respectively.

compared dosimetric quality of single‐energy partial‐arc (30°–165°

This is due to the greater proportion of PD delivered from lateral

and 195°–330°) VMAT plans with that of a single‐energy full‐arc

direction. In future studies, the potential of MEPAs technique can

(0°–359°) VMAT plans for prostate and demonstrated that partial

further be improved by optimizing the dose weighting factor for each

arcs technique results in lower doses to the bladder and rectum but

energy in MEPAs plans. The dose‐volume speciﬁcations for bladder

at an expense of higher doses to femoral heads.14 Our results, how-

complications are not as well studied as for rectum. Vargas et al. have

ever, cannot be directly compared against the previous studies, as to

reported that reductions in the low doses area for bladder have been

our knowledge, MEPA VMAT technique has not been reported pre-

associated with lower long‐term urinary side effects.31 MEPA (6/

viously. A study comparing single‐arc vs dual arcs VMAT for prostate

15 MV 1:2 weighted) reduced the volume covered by 20 and 30 Gy

cancer demonstrated superior OARs sparing using dual arcs tech-

by 2% compared 6 and 15 MV‐SA.

nique,23 whereas another study suggested single‐arc technique to be
17

superior over dual arcs VMAT for OARs sparing.

In Part 2 of this study, we investigated the sole effects of energy

Furthermore, it has been reported that dose ≥78 Gy to 50% of
the bladder volume results in the development of GU complications,32 which was not exceeded by any of the plans in this study. It

by comparing MEPAs (6/15 MV 1:1 weighted) with 6 and 15

is important to note here that maximum dose to bladder exceeded

MV‐PA with the same arc lengths and optimization parameters, by

65 Gy, especially in the overlapping region of bladder and the PTV,

MOMIN

|

ET AL.

63

F I G 5 . The dose distribution of a 6 MV‐
PA, a 15 MV‐PA, and a MEPA (6/15 MV
1:1 weighted) plan for one representative
case in sagittal views.
which involves the risk of Grade 3 toxicity as a late response.29

involved 15 MV, which raises a question of additional dose depos-

However, this was mainly due to not including maximum bladder

ited by photo‐neutrons produced in the linac head. This may be of

dose constraints during optimization for any of the three techniques.

some concern for MEPA (6/15 MV 1:2 weighted) technique as 2/3

This was because it is considered a strict constraint — required to

of the PD is delivered by 15 MV beam. One study on the measure-

be achieved by every single voxel of a structure, which, in turn,

ment of photo‐neutron dose at isocenter from an 18 MV linac

would require us to change the optimization parameters and opti-

showed that the total neutron equivalent dose is two to three orders

mize the plans individually. Instead, the goal was to optimize all the

of magnitude smaller than the photon dose delivered to the

plans with a ﬁxed optimization setup to highlight superiority among

patient.36 Nonetheless the amount of neutron dose in the vicinity of

different techniques. In terms of prostate motion, a greater prostate

the patient should not be neglected, which is one of the limitations

motion has been reported to occur in anterior and posterior direc-

of this study. Therefore, prior to clinically employing MEPA with

tion than lateral direction.33 Furthermore, it has been demonstrated

15 MV and higher, additional risks of secondary cancers due to

that intrafraction prostate motion from breathing is a major cause of

photo‐neutrons should be considered. Furthermore, mixed energies

34

Although lower MUs would reduce

VMAT involving higher energy would not be recommended for

the total treatment time resulting in lower probability of such organ

patients with pacemakers as it can result in the device malfunction.37

motion, the total treatment time for MEPAs technique, regardless of

Since the neutron production for higher energy (>10 MV) in FFF

the lower MUs, may not be reduced signiﬁcantly as two different

mode is reduced as much as 70%,29 similar mixed energy technique

energies need to be moded up at the console for each treatment

for ﬂattening ﬁlter free (FFF) modality would be an interesting topic

fraction.

for future investigation, though clinical use of FFF modality is cur-

prostate positional variation.

Historically, patient separation in anterior posterior direction

rently limited to ≤10 MV.

greater than 20 cm were considered as a threshold for using higher

Another limitation of our work is the same set of optimization

photon energy,35 the mean AP separation in our study was ~23 cm.

parameters including priority weighting factors used for all the

The rationale behind using the lowest clinical range (6 MV) to the

patients in Part 1 and 2 of this study. Our rationale behind maintain-

highest clinical range (15 MV) was to exploit the maximum differ-

ing same parameter set was to ensure that the differences were only

ence in dose deposition. Both MEPAs techniques in this study

due to energy and dose weighting selection in Part 1, and energy
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comparison to justify a superior treatment planning technique for
each part of this study. However, in practice, the optimization

This study investigated the potential scope of using MEPAs VMAT

parameters of MEPAs plans speciﬁc to individual patients and corre-

technique to treat prostate cancer compared to single‐energy

sponding treatment planning goals can further improve quality of

VMAT techniques. In Part 1 of this study, MEPAs (6/15 MV 1:2

MEPAs plans including reductions in maximum doses to bladder and

weighted) plans were found to be superior in sparing bladder and

femoral heads.

rectum, but resulting in slightly reduced target homogeneity com-

In terms of implications of MEPAs technique to clinical work‐

pared to either 6 and 15 MV‐SA plans. In Part 2 of this study, the

ﬂow, determining an ideal proportion of PD dedicated to each of the

impact of multiple energies alone was investigated by equally

selected energies would be crucial to achieve desired dosimetric out-

weighting both 6 and 15 MV in MEPAs (6/15 MV 1:1 weighted)

come. However, given that current TPS does not allow the optimiza-

and comparing with single‐energy partial arcs (6 and 15 MV‐PA).

tion of proportion of PD dedicated to each energy for a mixed

MEPAs (6/15 MV 1:1 weighted) plans resulted in improved target

energy VMAT plan, determining an ideal proportion of PD dedicated

dose conformity and, lower doses to bladder and rectum compared

to each energy in MEPAs plan would require a trial and error pro-

to 6 and 15 MV‐PA. In both parts, however, mixed energy VMAT

cess, especially with different combination of energies and dose

plans increased doses to femoral heads compared to single‐energy

weighting factors. For instance, MEPAs can also be used in combina-

VMAT plans.

tion of 6 and 10 MV, which has less concerns of production of secondary neutrons in comparison to the combination of energies used
in this study, 6 and 15 MV. We used the lowest and highest clinical
MV range to exploit the maximum difference in dose deposition.

CONFLICT OF INTEREST
None.

Nevertheless, once established, MEPAs can easily be implemented
for post optimization stages (i.e, patient speciﬁc QA) as the patient
speciﬁc QA for MEPAs plans can be performed similarly to that of a
single‐energy VMAT plans. This study was based on comparisons of
TPS generated dosimetric outcomes. Any quality assurance of these
plans was not considered as it was beyond the scope of this work.
Finally, the radiobiological impact of any of the techniques used in
this study was not investigated.
The TPS used in this study (RapidArc™, Eclipse, Palo Alto, CA,
USA) does not allow optimization of a single plan with two different
energies. Therefore, a composite plan was generated by summing a
lower energy and a higher energy plan. Beside the TPS used in this
study, the RayStation™ (Raysearch Laboratories, Stockholm, Sweden)
and the Monaco™ (Elekta, Stockholm, Sweden) are two major treatment planning systems that are currently being used to optimize
VMAT treatment plans. However, to our knowledge, no current
treatment planning system, including the one used in this study,
allows simultaneous optimization of two different energies. The current study, thus, involved the manual selection of dose weighting
per energy to achieve the desire dosimetric outcome. An algorithm
that simultaneously optimizes for both energies is necessary as it
will generate a plan with an optimal proportion of PD dedicated to
each energy, which, in turn, will further improve the quality of a
mixed energy VMAT plan. While it was beyond the scope of this
work to investigate the most suitable TPS for MEPAs technique, it
would be interesting to investigate MEPAs on RayStation™, which
utilizes multicriteria optimization where the user navigates through
many pareto optimal plans to arrive at a plan with desired dosimetric tradeoffs. However, the dosimetric comparisons between two
plans may not be suitable for RayStation™ as due to selection of
best possible tradeoff between different dose‐volume objectives of
various structures, the parameters may not remain same in the two
plans.
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